Drug Details

General Information of the Drug (ID: DR3226)
Name
Bis-chloroethylnitrosourea
Disease Brain cancer [ICD-11: 2A00] Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Noscapine      Papaver somniferum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression CASP3  Molecule Info 
Pathway MAP
Up-regulation Expression PARP1  Molecule Info 
Pathway MAP
                    In-vitro Model U87/DK CVCL_3428 Glioblastoma Homo sapiens
                    In-vivo Model For a xenograft model, 4*106 U87MG cells were inoculated subcutaneously into one flank of 5-6 weeks old, female nude mice.
                    Experimental
                    Result(s)		 NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects.
Target and Pathway
Target(s) Telomerase protein component 1 (TEP1)  Molecule Info  [3]
References
Reference 1 Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma. Oncology. 2017;93(1):43-50.
Reference 2 Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin. 2013 Jul;34(7):930-8.
Reference 3 KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study. Hepatobiliary Pancreat Dis Int. 2019 Feb;18(1):62-66.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link